Back to Results

Biogaia AB ADR (BIOGY)

Featured in Bullish Trend Stocks

BioGaia AB ADR is a depositary receipt listed on OTC Markets that reflects the common stock of BioGaia AB (publ), a Sweden-based healthcare company incorporated in 1990 and headquartered in Stockholm. Through its ADR structure, the listed security represents exposure to the issuer’s ordinary shares rather than a separate operating business. BioGaia develops, manufactures, markets, and sells probiotic products aimed at gut, oral, and immune health across Europe, the Middle East, Africa, the United States, the Asia-Pacific region, Australia, and New Zealand. Its operations are organized into Pediatrics, Adult Health, and Other segments. The Pediatrics segment includes drops, oral rehydration solutions, gut health tablets, and cultures used in infant and milk formula, while Adult Health covers gut health tablets, bone health tablets, oral health lozenges, and related cultures. The Other segment includes packaging solutions, and sales are made through distribution partners and direct channels.


Stock Summary Fair Value Profitability & Growth Quality & Risk Events & Dividends Market Outlook FAQ

Jump directly to the stock analysis sections supported by the latest available data.

Data update note: Fair value and stock analysis metrics are updated after regular market sessions when new data becomes available.
Ticker Fair Value Fair Value Upside/Downside Fair Value Rating Analyst Price Target Analyst Target Upside/Downside Overall Financial Health Dividend Yield Next Earnings Date P/E Ratio Price-to-Book Ratio Price-to-Sales Ratio Market Cap Enterprise Value Total Debt / Total Capital Free Float / Shares Outstanding Altman Z-Score Payout Ratio Free Cash Flow / Net Income
OTC-BIOG.Y
$10.08
-16.0% Downside
Fair
Not available
Not available
Great
2.3%
October 21, 2026
31.6x
10.0x
7.0x
1.122 B
1.087 B
0.0%
83.0%
14.7
59.4%
86.3%
Valuation • Fair Value

Biogaia AB ADR (OTC-BIOG.Y) Fair Value by Valuation Model

Review the available estimates for Biogaia AB ADR (OTC-BIOG.Y), including DCF Fair Value, Ben Graham Formula Value, DDM Fair Value, Comps Fair Value.

Primary Valuation Read

Fair Value

$10.08

Estimated downside of 16.0% versus the current market price.

Fair Value Confidence

High

Confidence level for the primary fair value estimate.

DCF Fair Value

$10.50

Discounted cash flow valuation reference.

Ben Graham Formula Value

$3.38

Classic Ben Graham valuation formula reference.

DDM Fair Value

$9.60

Dividend discount model valuation reference.

Comps Fair Value

$9.82

Comparable-company valuation reference.

Analyst Price Target

Not available

Data is currently unavailable.

How to read these valuation models

Use the 6 available valuation references for Biogaia AB ADR (OTC-BIOG.Y) as analytical inputs, not a standalone conclusion. Valuation methods can differ because they rely on different assumptions, time horizons and financial inputs; compare the estimates with the current price and the company’s financial quality.

Profitability • Growth

Profitability & Growth for Biogaia AB ADR (OTC-BIOG.Y)

Review the profitability and growth indicators currently supported by the latest data.

Revenue

163 M

Current operating scale indicator.

Revenue Forecast

169.7 M

Forward revenue estimate.

EBITDA

46.885 M

Current operating profitability reference.

EBITDA Forecast

52.662 M

Forward operating profitability estimate.

How to read profitability and growth

This section helps investors review Biogaia AB ADR (OTC-BIOG.Y) from an operating perspective by combining current scale, forward revenue expectations and EBITDA-related profitability measures.

Quality • Risk

Quality & Financial Risk for Biogaia AB ADR (OTC-BIOG.Y)

Review the financial quality and risk indicators currently supported by the latest data.

Financial Health

Great

Positive financial-health read.

Piotroski Score

7

Relatively strong quality score.

Altman Z-Score

14.7

Relatively strong balance-sheet zone.

FCF / Net Income

86.3%

Cash conversion quality indicator.

How to read quality and risk

This section combines quality, balance-sheet and accounting-risk indicators for Biogaia AB ADR (OTC-BIOG.Y). Read the metrics together: no single score is a complete investment conclusion, but the combined view can highlight financial strength, earnings quality and areas that may deserve closer review.

Events • Dividends

Upcoming Events & Dividends for Biogaia AB ADR (OTC-BIOG.Y)

Track the upcoming dates and dividend metrics currently supported by the latest data.

Next Earnings Date

October 21, 2026

Days to Earnings

29

Dividend Yield

2.3%

Current income yield reference.

Payout Ratio

59.4%

Dividend payout reference.

How to read events and dividends

This section helps investors track time-sensitive items for Biogaia AB ADR (OTC-BIOG.Y), including the next earnings date and dividend-related milestones. These items can matter for short-term volatility, income planning and event-driven positioning.

Technical Outlook

Technical Signals by Time Frame

Review the technical signals currently available for this stock across supported time frames.

Technical Signals by Time Frame

Switch between time frames to review the current technical signal for the stock.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: 15-minute • intraday
Strong Buy

The 15-minute technical read for Biogaia AB ADR (OTC-BIOG.Y) is currently Strong Buy. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: 1-hour • short-term
Strong Buy

The 1-hour technical read for Biogaia AB ADR (OTC-BIOG.Y) is currently Strong Buy. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: daily • daily
Strong Buy

The daily technical read for Biogaia AB ADR (OTC-BIOG.Y) is currently Strong Buy. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: weekly • weekly
Strong Buy

The weekly technical read for Biogaia AB ADR (OTC-BIOG.Y) is currently Strong Buy. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: monthly • monthly
Strong Buy

The monthly technical read for Biogaia AB ADR (OTC-BIOG.Y) is currently Strong Buy. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

FAQ • Fast Investor Answers

Biogaia AB ADR (OTC-BIOG.Y) Stock FAQ

Data-supported answers about Biogaia AB ADR (OTC-BIOG.Y), including explicit coverage status where a reliable valuation estimate is not currently available.

Fair Value
$10.08
Estimated downside 16.0%
Valuation Rating
Overvalued
Estimated downside of 16.0%
Financial Health
Great
Current financial-health read

The current fair value estimate for Biogaia AB ADR (OTC-BIOG.Y) is $10.08. This implies an estimated downside of 16.0% versus the current market price.

Based on the current fair value estimate, the stock appears overvalued, with estimated downside of 16.0% versus the current market price.

The current financial health read for Biogaia AB ADR (OTC-BIOG.Y) is Great. This should be reviewed alongside valuation, profitability, debt and cash-flow quality metrics.

The next earnings date currently listed for Biogaia AB ADR (OTC-BIOG.Y) is October 21, 2026.

Based on the current data, dividend yield is 2.3%.

The current P/E ratio listed for Biogaia AB ADR (OTC-BIOG.Y) is 31.6x. Use it together with growth, margins and sector comparisons rather than as a standalone valuation signal.

The current market capitalization listed for Biogaia AB ADR is 1.122 B.

The current enterprise value listed for Biogaia AB ADR is 1.087 B. Enterprise value can provide a broader valuation view than market capitalization alone because it also considers net debt.

The ticker symbol for Biogaia AB ADR is OTC-BIOG.Y, and the stock is listed on OTC Markets.

Biogaia AB ADR (OTC-BIOG.Y) is listed on OTC Markets.

The current debt-to-total-capital ratio listed for Biogaia AB ADR is 0.0%, which helps investors evaluate the company’s financing structure and leverage profile.

The free float listed for Biogaia AB ADR is 83.0%. Free float helps investors understand how much of the share base is available for public trading.

Similar Biotechnology Stocks View more on OTC Markets

Comparable companies from the same industry, limited to one security per issuer.

ABBV NYSE AbbVie Inc Fair Value Fair Market Cap 468.7 B
AMGN NASDAQ Amgen Inc Fair Value Fair Market Cap 221.8 B
GILD NASDAQ Gilead Sciences Inc Fair Value Fair Market Cap 189.3 B
VRTX NASDAQ Vertex Pharmaceuticals Inc Fair Value Fair Market Cap 130.5 B
REGN NASDAQ Regeneron Pharmaceuticals Inc Fair Value Undervalued Market Cap 80.273 B
MRNA NASDAQ Moderna Inc Fair Value Overvalued Market Cap 72.885 B
ARGX NASDAQ argenx NV ADR Fair Value Fair Market Cap 61.249 B
NTRA NASDAQ Natera Inc Fair Value Overvalued Market Cap 56.346 B
ONC NASDAQ BeOne Medicines AG DRC Fair Value Fair Market Cap 41.851 B
RVMD NASDAQ Revolution Medicines Inc Fair Value Fair Market Cap 41.337 B
ALNY NASDAQ Alnylam Pharmaceuticals Inc Fair Value Fair Market Cap 33.673 B
BIIB NASDAQ Biogen Inc Fair Value Fair Market Cap 33.298 B
ROIV NASDAQ Roivant Sciences Ltd Fair Value Overvalued Market Cap 27.607 B
INSM NASDAQ Insmed Inc Fair Value Fair Market Cap 26.385 B
INCY NASDAQ Incyte Corporation Fair Value Fair Market Cap 25.728 B
BNTX NASDAQ BioNTech SE Fair Value Fair Market Cap 25.339 B
UTHR NASDAQ United Therapeutics Corporation Fair Value Fair Market Cap 21.342 B
GMAB NASDAQ Genmab AS Fair Value Overvalued Market Cap 20.853 B
ASND NASDAQ Ascendis Pharma AS Fair Value Fair Market Cap 15.602 B
NBIX NASDAQ Neurocrine Biosciences Inc Fair Value Undervalued Market Cap 14.46 B